DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor–resistant lung cancer therapy

Acquired resistance to inhibitors of anaplastic lymphoma kinase (ALK) is a major clinical challenge for ALK fusion-positive non-small-cell lung cancer (NSCLC). In the absence of secondary ALK mutations, epigenetic reprogramming is one of the main mechanisms of drug resistance, as it leads to phenoty...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Haejeong, Kim, Jong-Hwan, Lim, Hyun Jung, Kim, Jeong-Hwan, Kim, Miso, Koh, Jaemoon, Im, Joo-Young, Kim, Bo-Kyung, Won, Misun, Park, Ji-Hwan, Shin, Yang-Ji, Yun, Mi Ran, Cho, Byoung Chul, Kim, Yong Sung, Kim, Seon-Young, Kim, Mirang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440127/
https://www.ncbi.nlm.nih.gov/pubmed/35999456
http://dx.doi.org/10.1038/s12276-022-00836-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440127/
https://www.ncbi.nlm.nih.gov/pubmed/35999456
http://dx.doi.org/10.1038/s12276-022-00836-7

Ejemplares similares